Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice

The outcome of high-risk myelodysplastic syndrome (MDS) patients treated with 5-azacitidine (5-AZA) in the real-life setting remains largely unknown. We evaluated 110 MDS patients (IPSS intermediate 2/high) treated outside of clinical trials at a single institution between September 2003 and January...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2019-08, Vol.98 (8), p.1919-1925
Main Authors: Scalzulli, Emilia, Molica, Matteo, Alunni Fegatelli, Danilo, Colafigli, Gioia, Rizzo, Lorenzo, Mancini, Marco, Efficace, Fabio, Latagliata, Roberto, Foà, Robin, Breccia, Massimo
Format: Article
Language:English
Subjects:
Blood diseases
Clinical medicine
Clinical trials
Deoxyribonucleic acid
DNA
DNA methylation
Hematology
Leukemia
Medical prognosis
Medicine
Medicine & Public Health
Myelodysplastic syndromes
Oncology
Original Article
Working groups
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The outcome of high-risk myelodysplastic syndrome (MDS) patients treated with 5-azacitidine (5-AZA) in the real-life setting remains largely unknown. We evaluated 110 MDS patients (IPSS intermediate 2/high) treated outside of clinical trials at a single institution between September 2003 and January 2017. Median duration of therapy was 9.5 cycles. The overall survival (OS) of the whole cohort was 66.1% at 1 year and 38.3% at 2 years. No differences in terms of OS were observed with regard to gender ( p =  0.622) and age at baseline ( 75 years, p  = 0.075). According to the IPSS-R, the very high-risk group had an inferior 2-year OS (17%) compared with intermediate-group patients (64%, p  
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-019-03724-9